CAR T CELL THERAPY MARKET ANALYSIS

Chimeric antigen receptor (CAR)-T cell therapy is a type of gene cell therapy in which the T cells are used to kill the cancer cells. There are basically three steps involve in CAR T cell therapy which included: collecting of T cells, engineering of T cells, and infusing the CAR T cells in human body. Chimeric antigen receptor (CAR)-T cell therapy is a T cell immunotherapy in which body’s own immune system is utilized to fight cancer. Cytokine release syndrome (CRS) is a serious complication of CAR T cell therapy in which CAR T cell release chemicals called cytokines and cause reaction from the immune systems these reactions includes: Fever and chills, fatigue, nausea, diarrhea, low blood pressure, difficulty in breathing, and etc.

Global CAR T cell therapy market is estimated to be valued at US$ 2.26 Billion in 2022 and is expected to exhibit a CAGR of 20.9 % during the forecast period (2022-2030).

Figure 1.Global CAR T Cell Therapy Market Share (%), by Targeted Antigen, 2022

To learn more about this report, request sample copy

Global CAR T Cell Therapy Market - Drivers

Increasing prevalence of cancer is expected to propel growth of the global CAR T cell therapy market during the forecast period. For instance, in February 2022, the World Health Organization (WHO) published a fact sheet according to which, every year around 400,000 children develop cancer and 2.26 million cases of breast cancer were found in 2021, globally.

Furthermore, key companies focusing on product approval is expected to propel growth of the global CAR T cell therapy market during the forecast period. For instance, in April, 2022, Kite Pharma, Inc., a subsidiary of Gilead Sciences, Inc., one of the research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, obtained the U.S. Food and Drug Administration approval for Yescarta for initial treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Figure 2.Global CAR T Cell Therapy Market Share (%), by Region, 2022

To learn more about this report, request sample copy

Global CAR T Cell Therapy – Impact of Coronavirus (COVID-19) Pandemic:

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another. Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to a November 2022 published World Health Organization’s report, manifestation of coronavirus (COVID-19) has resulted in more than 632,533,408 confirmed cases infected by COVID-19 worldwide as of 15 November 2022.

Furthermore, COVID-19 pandemic has a significance impact on cancer patients due to use of CAR-T cell therapy for SARS-CoV-2. For instance, in April 2020, a data published by Duke-NUS, a school of National University of Singapore according to which CAR-T cell therapy can be used for treatment of SARS-CoV-2 and other infectious disease.

Global CAR T Cell Therapy Market: Key Developments

In June 2022, Bristol-Myers Squibb Company, one of the global leader in Biopharmaceutical company, obtained the U.S. Food and Drug Administration (FDA), approval for Breyanzi CAR T cell therapy for the treatment of relapsed or refractory large B-cell lymphoma after one prior therapy. Approval was based on data from the Phase 2 pilot company-sponsored study of a CAR T cell therapy in patients with primary refractory or relapsed LBCL.

In February, 2022, Johnson & Johnson Services, Inc., one of the largest healthcare company, announced that, the U.S. Food and Drug Administration approved CARVYKTI (ciltacabtagene autoleucel), a BCMA-Directed CAR-T Immunotherapy for the treatment of Patients with Relapsed or Refractory Multiple Myeloma.

Global CAR T Cell Therapy Market: Restraint

The major factor that hinder growth of the global CAR T cell therapy market include the side effects of CAR T cell therapy. For instance, in March, 2022, American Cancer Society, a nationwide voluntary health organization, published a data according to which there are many possible side effects of CAR T cell therapy which includes: high fever and chill, trouble breathing, severe nausea, vomiting, and/or diarrhea, feeling dizzy or lightheaded, headaches, fast heartbeat, feeling very tired, muscle and/or joint pain etc.

Global CAR T Cell Therapy market- Key Players

Major players operating in the global CAR T cell therapy market include Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Novartis AG, CARsgenTherapeutics Co.,Ltd, Aurora Biopharma, Legend Biotech, Gilead Sciences, Inc., Pfizer Inc., bluebird bio, Inc., Sorrento Therapeutics, Inc., Mustang Bio, Fate Therapeutics among other prominent players.